title: [Clinical study of prophylactic therapy of interferon on postoperative renal cell carcinoma].
abstract: A clinical trial using interferon alpha 2b (IFN alpha-2b) for prophylactic therapy was done on 44 patients who had received nephrectomy for renal cell carcinoma. Principally, the daily intramuscular injection of 3 of 6 million units of IFN alpha-2b was done for 4 consecutive weeks after 2 weeks postoperatively and thereafter followed by injection once every 2 weeks. The clinical evaluation was done for the recurrence rate, the survival rate, the IFN alpha and IFN gamma producing ability, the activity of 2',5' oligoadenylate synthetase (2-5AS) and the side effect. Out of 44 cases entered, 42 were completely evaluable and recurrence was observed in 5 (11.9%) of the 42 cases. The recurrence rate was 5.5% and 16.4%, at the first and second year, respectively. Three (7.1%) of the 42 patients died. The survival rate was 97.6% at the first year, 89.7% at the second year for the followup study. The IFN alpha producing capacity was low in all of the 4 evaluable cases. The IFN gamma producing capacity was high in 3 cases and normal in 1 case. 2-5AS, the enzyme produced by IFN, was activated by IFN alpha-2b administration in all of the 4 evaluable cases. Side effects were observed in 24 (54.5%) of the 44 cases. The main side effect was fever. Leucopenia, general fatigue, appetite loss, temporary elevation of liver transaminase were also observed. However, there were only 5 cases (11.4%) in which administration of IFN alpha-2b had to be discontinued.
authors.affiliation: Department of Urology, Osaka City University Medical School.
authors.forename: R
authors.initials: R
authors.lastname: Yasumoto
authors.forename: M
authors.initials: M
authors.lastname: Asakawa
authors.forename: N
authors.initials: N
authors.lastname: Hayahara
authors.forename: T
authors.initials: T
authors.lastname: Maekawa
authors.forename: S
authors.initials: S
authors.lastname: Wada
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
authors.forename: M
authors.initials: M
authors.lastname: Maekawa
authors.forename: Y
authors.initials: Y
authors.lastname: Morikawa
authors.forename: J
authors.initials: J
authors.lastname: Kawakita
authors.forename: M
authors.initials: M
authors.lastname: Umeda
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000517:prevention & control* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000401:mortality / Q000517:prevention & control* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009392:Nephrectomy; D011182:Postoperative Care; D011994:Recombinant Proteins; D015996:Survival Rate
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins